Franchise businesses have long been plagued by scandals. Domino’s is just the latest

Jenny Buchan, UNSW Sydney

The blue and red boxes with white dots are immediately recognisable as containing Domino’s pizzas. The pizza chain is Australia’s largest and is run as a franchise, with the ASX-listed public company Domino’s Pizza Enterprises holding the Australian master franchise rights.

Industry analysts IBISWorld calculate Domino’s has 4.2% of the fast food and takeaway market in Australia.

But recent reports suggest all is not well with many of the store owners, who are struggling with rising costs and declining profitability.

Troubling reports

The central issue appears to be what the federal government describes in its code of conduct as the “the imbalance of power between franchisors and franchisees”.

The Australian Financial Review has reported troubling claims in two key areas:

  • Domino’s appears to have doubled the margin on the key food ingredients it sells to franchisees and increased its advertising levy, according to a letter from store owners represented by the Australian Association of Franchisees. This could reduce their profitability

  • Domino’s Australian chief operating officer, Greg Steenson, reportedly encouraged franchisees in a presentation to take advantage of restructuring schemes that allow insolvent companies to continue to trade by negotiating repayment plans with the tax office and other creditors.

In a letter to Domino’s quoted in the report, the franchisees said their earnings have remained flat for 15 years, and have not kept up with inflation.

A long history of disputes

A former franchisee told a parliamentary inquiry into the franchising model the margin squeeze meant

franchisees can be ripped off by [Domino’s Pizza Enterprises] when forced to buy supplies at a higher price than they could get through their wholesalers.

He said the cost of food, labour, rent and other fixed costs had risen, but in 2019 pizzas were still sold at 1990s prices. “Nobody is left to pay for this but the franchisees,” the former owner said.

According to the Financial Review article, the cost of supplies remains a problem for franchisees. Time will tell whether Domino’s proposed 70 cent increase in pizza prices will help.

In response to questions from the Financial Review, Domino’s said the food margin had not “materially changed” in five years, despite volatility in ingredients prices.

Government reviews found the previous regulations had loopholes that did not sufficiently protect franchisees. There have been a string of high-profile disputes involving auto services company Ultra Tune, coffee chain 85 Degrees Coffee, Pizza Hut and others.

Following a 2024 inquiry, changes to the code of conduct were introduced this year.

Advertising costs on the rise

Advertising expenditure comes from what is now known as a “special purpose fund” in the code of conduct. Franchisors need to provide franchisees with disclosure about how the money is spent.

In 2017, the consumer regulator Australian Competition and Consumer Commission fined Domino’s A$18,000 for allegedly slipping on its obligations to advise franchisees about its marketing spend.

Ensuring franchisees have a genuine say in how their increased contribution is spent could help to address any imbalance of power between Domino’s and its franchisees.

Franchisees reportedly now pay 6% of their earnings to Domino’s for marketing and advertising, up from 5.35%. That is in addition to 7% of gross sales paid as royalties, and other costs for email and bookkeeping.

What insolvent means

The insolvency law for small businesses is explained by the Australian Taxation Office as a process that enables financially distressed but viable firms to restructure their existing debts and continue to trade.

The press reports say the franchisees of about 65 Domino’s stores were on repayment plans with the Australian Taxation Office. Many franchisees own two or more outlets.

Under the Corporations legislation, companies on these repayment plans may be trading insolvent, or believe they will become insolvent. Insolvent means they cannot pay their debts when they fall due. If this is the case, a key question that needs to be answered by Domino’s is whether their franchised outlets can become profitable.

In another media report, Domino’s was quoted as saying it disputed the number of stores on repayment plans, adding it was a “significantly smaller” number of franchisees.

The company was contacted for comment but did not respond before deadline.

What this means for the stores

So what does this mean for Domino’s store owners who may be trading insolvent?

Under the law, the restructuring process allows eligible small business companies:

  • to retain control of the business, property and affairs while developing a plan to restructure with the assistance of a small business restructuring practitioner
  • to enter into a restructuring plan with creditors.

If a company proposes a restructuring plan to its creditors, it is taken to be insolvent. This is a game changer for the franchisee and its creditors.

Franchisees receive protection from creditors who want to enforce rights under existing contracts. A franchisee’s creditors include suppliers, its landlord, employees, the tax office and the franchisor (in this case, Domino’s).

Currently these store owners are protected from any creditors pushing them to pay their debts. The restructuring process gives the store owners some breathing room while the debt negotiations take place.

The imbalance of power persists

Despite government inquiries and reviews, it seems the imbalance of power between the Domino’s franchisees and their franchisor persists.

But Domino’s can’t afford to stay the same. Franchisees need to make a profit. The move to enter restructuring could be a temporary band aid.

Domino’s largest shareholder and executive chairman, Jack Cowin, was appointed in July after the former chief executive left after just seven months. Cowin understands the franchised fast food sector and has pledged to lead a cost reduction program that will improve the profitability of stores.The Conversation

Jenny Buchan, Emeritus Professor, Business School, UNSW Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read More........

HIV breakthrough stalled by red tape barriers in India


Dimapur, (MExN): India faces a critical moment in its effort to end AIDS nationally and globally as regulatory delays and patent-related barriers threaten access to lenacapavir, a groundbreaking long-acting HIV prevention medicine, health experts and activists warned today.

A press release from LEN-LA for All Coalition and MSF said that Lenacapavir confers virtually 100% protection against HIV infection and has been widely recognised by UNAIDS, WHO, and other technical normative agencies as a significant advance that can bring new infections under control. However, regulatory hurdles in India and patent filings by Gilead Sciences risk obstructing timely access for marginalised communities most affected by HIV, including sex workers, transgender persons, gay men and other men who have sex with men, people who use drugs, and young women and girls.

Key populations account for a disproportionate share of new HIV infections. Globally, outside sub-Saharan Africa, two out of three new infections occur among key populations and their sexual partners. Overall, new HIV infections have remained virtually unchanged for the past three years, highlighting the urgent need for more effective prevention tools deployed at scale.

“Indian manufacturers can reduce the price of generic lenacapavir to US$25–40 (Rs. 2,225 - 3,560) per person per year, which would be a game changer for countries such as South Africa, which has the highest number of new HIV infections in the world. Unnecessary regulatory delays will mean India cannot supply generic lenacapavir in 2026, weakening its role in supplying affordable HIV medicines for the world,” said Fatima Hassan of South Africa's Health Justice Initiative. “This will have a devastating effect across low- and middle-income countries that depend on Indian generics, and especially countries like ours that are being targeted by the Trump administration by arbitrary exclusion from the Gilead / PEPFAR global rollout program. We need generics urgently to save lives.”

Under India’s New Drugs and Clinical Trials Rules (NDCTR) 2019, companies may seek a waiver of the requirement to conduct local clinical trials if a medicine has been approved by the drug regulatory authorities of the US (USFDA), European Union (EMA), or other specified countries and offers a “significant therapeutic advance.” Lenacapavir has met these criteria. Without such a waiver, the timely introduction of Indian generics globally could be substantially hindered.

“Few medical interventions demonstrate such remarkable efficacy. In clinical trials, lenacapavir has shown 100% effectiveness in preventing HIV among cisgender women and girls, and a 96% reduction in HIV risk within a gender-diverse group that includes cisgender men, transgender men, and non-binary individuals. Now we need the policies that will allow us to deliver this superior protection tool to all who need it, including a waiver of India’s requirement for national clinical trials,” said Dr Antonio Flores, Senior HIV/TB Advisor, MSF.

Community networks said that delays could have immediate and severe consequences. “Access to more effective HIV prevention tools like lenacapavir from the HIV programme free of cost is vital because our exposure to HIV through sex work is a daily worry for us,” said Dr Protim Ray, representative of Kolkata-based, sex worker–led collective Durbar Mahila Samanwaya Committee. “When revolutionary prevention tools like lenacapavir are delayed or locked behind red tape, it’s not just policy — it’s our lives at stake.”

In addition to regulatory barriers, health groups including the Third World Network have raised concerns about Gilead’s patent filings in India, arguing that the claims may lack sufficient novelty. If granted, the patents could restrict open competition among generic manufacturers producing active pharmaceutical ingredients (API) and finished formulations, undermining India’s capacity to manufacture and supply affordable generics. Although Gilead has granted royalty-free, non-exclusive licenses to six generic manufacturers, including four Indian companies, to supply lenacapavir to 120 low- and lower-middle-income countries and territories, key regions with high HIV incidence among key populations, including parts of Latin America, are excluded. This undermines equitable global access and restricts local production.

Granted patents in India will prevent Indian generic companies that have not been licensed by Gilead from supplying locally or to countries excluded from Gilead's list of 120 eligible countries. Advocates say Gilead’s multiple patent claims must be expeditiously rejected.“A decisive action is urgently needed. Regulatory authorities, patent offices, and global partners must work together to ensure that long-acting HIV prevention becomes accessible without delay, and that communities most at risk are not once again left behind,” said Eldred Tellis of the global LEN-LA for All Coalition. This coalition includes Health GAP (Global), the Health Justice Initiative (South Africa), Sankalp Rehabilitation Trust (India), Just Treatment (UK), and ABIA (Brazil). HIV breakthrough stalled by red tape barriers in India | MorungExpress | morungexpress.com
Read More........

Rupee crashes to record low beyond 90 per dollar


(AI Image/IANS)

New Delhi, (IANS) The Indian rupee fell sharply on Wednesday, slipping past the crucial 90-per-dollar level for the first time ever.

The currency dropped to a new record low of 90.13 against the US dollar, breaking its previous all-time low of 89.9475 touched just a day earlier.

The decline in the rupee came amid weak trade and portfolio flows, along with growing uncertainty over the India-US trade deal.

These factors kept the currency under continuous pressure throughout the session.

The sharp fall in the rupee also weighed on domestic equity markets. The Nifty index slipped below the 26,000 mark -- reflecting cautious sentiment among investors.

The Sensex also dropped nearly 200 points in early trade as the weakening currency raised concerns about inflation and foreign investor activity.

Analysts said that the market mood remained tense as traders watched for signs of stability in the rupee and clarity on trade negotiations between India and the United States.

“The rupee depreciation will halt and even reverse when the India-US trade deal materialises. This is likely this month. A lot, however, will depend on the details of the tariffs to be imposed on India as part of the deal,” analysts stated.

Meanwhile, the Indian stock market opened on a quiet note on Wednesday, with both benchmark indices showing minimal movement in early trade.

The Sensex inched up by just 12 points to 85,151, while the Nifty slipped 18 points to 26,014.

At the opening bell, shares of HUL, Titan, Tata Motors PV, NTPC, BEL, Trent, Bajaj Finserv, Kotak Bank, Ultratech Cement, Maruti Suzuki, L&T, Power Grid, and ITC were among the top losers in the morning session.

“A real concern now, which has contributed to the slow drifting down of the market, is the continued depreciation in the rupee and fears of further depreciation since the RBI is not intervening to support the rupee,” analysts stated.“This concern is forcing the FIIs to sell despite the improving fundamentals of rising corporate earnings and strong rebound in GDP growth,” they added. Rupee crashes to record low beyond 90 per dollar | MorungExpress | morungexpress.com
Read More........